热门资讯> 正文
BioXcel重新遵守纳斯达克上市规则
2025-09-18 19:41
- BioXcel Therapeutics (NASDAQ:BTAI) has regained compliance with Nasdaq’s market value of listed securities (MVLS) requirement for continued listing on the exchange.
- On March 20, 2025, the company was notified by Nasdaq that it was not in compliance as its MVLS was below $35.0 million for 30 consecutive business days.
- Source: Press Release
More on BioXcel Therapeutics
- BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call (Transcript)
- BioXcel Therapeutics, Inc. (BTAI) Discuses On SERENITY At-Home Pivotal Phase 3 Safety Trial Results Call - Slideshow
- BioXcel whipsaws after late-stage trial win for lead asset
- Seeking Alpha’s Quant Rating on BioXcel Therapeutics
- Historical earnings data for BioXcel Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
